NCRI

Mitsubishi Tanabe Pharma America Announces Presentations in ALS at 34th International Symposium on ALS/MND

Retrieved on: 
Tuesday, December 5, 2023

JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.

Key Points: 
  • JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.
  • MTPA's posters will be displayed during poster sessions held in the Event Halle on December 6 and 7.
  • A Preliminary Analysis of Oral Edaravone-Treated Patients with Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database (Malgorzata Ciepielewska, M.S.
  • ; State University of New York Upstate Medical University)
    Poster Session B (Part 1), 5:45 p.m. – 6:45 p.m. CET, Dec. 7

Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control

Retrieved on: 
Tuesday, October 10, 2023

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of a post hoc analysis in the peer-reviewed medical journal, Annals of Clinical and Translational Neurology comparing the long term survival of participants in the CENTAUR study versus a historical clinical trial control group.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of a post hoc analysis in the peer-reviewed medical journal, Annals of Clinical and Translational Neurology comparing the long term survival of participants in the CENTAUR study versus a historical clinical trial control group.
  • The post hoc survival analysis published today compared CENTAUR clinical trial participants who received AMX0035 against a propensity score-matched, AMX0035-naïve external control cohort from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.
  • These results using an external control aligned with prior analysis using statistical models adjusting for placebo-to-active crossover in CENTAUR ( RPSFTM ).
  • Amylyx donated data from the CENTAUR clinical trial to the PRO-ACT database.

Mitsubishi Tanabe Pharma America Showcases Depth of ALS Research with Wide Range of Abstracts at 22nd Annual NEALS Meeting

Retrieved on: 
Wednesday, October 4, 2023

JERSEY CITY, N.J., Oct. 4, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that eight presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held in Clearwater, Fla., from October 4-6.

Key Points: 
  • JERSEY CITY, N.J., Oct. 4, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that eight presentations in amyotrophic lateral sclerosis (ALS) will be shared at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting, being held in Clearwater, Fla., from October 4-6.
  • Presentations include:
    A preliminary analysis of demographics and clinical characteristics in people with ALS being treated with RADICAVA ORS, utilizing U.S.-based administrative claims data from Optum's Clinformatics® Data Mart (CDM), will be presented.
  • REFINE-ALS is a NEALS-affiliated clinical trial sponsored by MTPA and conducted in collaboration with the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH).
  • Real-World Survival Effectiveness of Edaravone in Amyotrophic Lateral Sclerosis: A Propensity Score Weighted, Registry-based, Canada-wide Cohort Study
    Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients With Amyotrophic Lateral Sclerosis

PatientsLikeMe Shares Amyotrophic Lateral Sclerosis (ALS) Data to Expand PRO-ACT Database

Retrieved on: 
Wednesday, May 17, 2023

With this collaboration, the company’s outcomes-rich data is now freely available to the international research community.

Key Points: 
  • With this collaboration, the company’s outcomes-rich data is now freely available to the international research community.
  • This dataset will be a significant addition to Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database comprising anonymized data from 29 clinical trials and 11,685 patient-records.
  • With this arrangement, data from over 14 thousand people living with ALS comprising the PLM ALS database will be a substantial enhancement available to ALS researchers like PRO-ACT.
  • “ALS is a devastating disease that is an integral part of our founding story,” said Chris Renfro-Wallace , Chief Operating Officer at PatientsLikeMe.

Bright Data 2023 Impact Report Highlights the Use of Public Web Data for Public Good

Retrieved on: 
Thursday, May 11, 2023

Bright Data , the industry-leading web data platform, today released its latest impact report in which it highlights the critical use of public information for public good.

Key Points: 
  • Bright Data , the industry-leading web data platform, today released its latest impact report in which it highlights the critical use of public information for public good.
  • The Bright Initiative by Bright Data, a pro bono program focused on using public web data to drive global change, expanded in 2023 and includes partnerships with over 700 organizations around the world.
  • NCRI uses The Bright Initiative by Bright Data’s tools to monitor publicly available web content across social media platforms.
  • To discover more about the positive impact The Bright Initiative is having on the world, visit: https://brightinitiative.com/ .

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials

Retrieved on: 
Thursday, August 4, 2022

We thank the people living with ALS who participated in our clinical trials to make this possible.

Key Points: 
  • We thank the people living with ALS who participated in our clinical trials to make this possible.
  • The PRO-ACT database, which is sponsored by the ALS Association and managed by The Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital, houses the largest ALS clinical trials dataset, containing nearly 11,000 ALS de-identified patient records from 23 completed clinical trials.
  • The platform harmonizes and merges anonymized data from existing publicly and privately conducted ALS clinical trials to generate a unique, freely available resource for the scientific community to help with finding cures for ALS.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Treadstone 71 releases details of hybrid operations and cognitive warfare actions by Iran

Retrieved on: 
Friday, July 22, 2022

HALF MOON BAY, Calif., July 22, 2022 /PRNewswire/ -- Treadstone 71, LLC, your primary source for cyber intelligence and counterintelligence training and services, released in-depth details of Iranian intelligence-backed hybrid operations and cognitive warfare actions.

Key Points: 
  • HALF MOON BAY, Calif., July 22, 2022 /PRNewswire/ -- Treadstone 71, LLC, your primary source for cyber intelligence and counterintelligence training and services, released in-depth details of Iranian intelligence-backed hybrid operations and cognitive warfare actions.
  • For example, they issue instructions to Basij Cyber Battalion members to start cyber operations against opposition groups such as the National Council of Resistance of Iran (NCRI)," stated Jeff Bardin, Chief Intelligence Officer at Treadstone 71.
  • These actions combined with physical infiltration of Iranian protests and demonstrations and distributed denial of service attacks shows a hybrid warfare approach to Iranian regime attacks against any opposition, internal and external."
  • With Putin's visit to Iran, Treadstone 71 expects Russian participation in anti-dissident operations.

University of Ottawa Taps Network Contagion Research Institute, Rutgers Miller Center as Strategic Partners in Disinformation Lab

Retrieved on: 
Friday, February 18, 2022

With disinformation being weaponized—disinformation-as-a-service is a thriving industry—by nation-states, political extremists, activists, and garden-variety criminals alike-- the Lab will leverage the expertise of NCRI and the Miller Center to focus on developing disinformation defenses, influencing policymaking, and building advanced tools to preserve the integrity of information. Four major outcomes will result from the new initiative: events to increase public awareness building thru public events, policy briefs and research papers on trends and patterns reports targeted to the disinformation concerns of particular organizations, and courses and training programs for capacity building and resilience.

Key Points: 
  • OTTAWA, Ontario, Feb. 18, 2022 /PRNewswire-PRWeb/ -- The Professional Development Institute (PDI) of the University of Ottawa, Canada, the largest bilingual (English/French) university in the world, today launched an Information Integrity Lab that includes the Network Contagion Research Institute (NCRI) and the Miller Center for Community Protection and Resilience at Rutgers University as key strategic partners.
  • "We are delighted to work with such influential thought leaders as the NCRI," says Serge Blais, Executive Director of the PDI.
  • Taken together, these proficiencies will power one of the most dynamic learning environments on this subject anywhere in the world," Blais says.
  • Besides NCRI and the Rutgers Miller Center, the Lab assembles a prestigious network of leading institutions in the disinformation space, including FX Innovation, the Atlantic Council's Digital Forensic Research Lab, and the International Commission of Jurists, Canadian Section.

Mitsubishi Tanabe Pharma America Presents REFINE-ALS Biomarker Study Details at Virtual 32nd International Symposium on ALS/MND

Retrieved on: 
Friday, December 10, 2021

Details were presented as part of theMotor Neurone Disease Association (MNDA)32nd International Symposium on ALS/MND, being held virtually December 7-10.

Key Points: 
  • Details were presented as part of theMotor Neurone Disease Association (MNDA)32nd International Symposium on ALS/MND, being held virtually December 7-10.
  • The U.S. Food and Drug Administration (FDA) approved RADICAVA (edaravone) IV on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).1 Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc.
  • You may report side effects to Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • About Mitsubishi Tanabe Pharma America, Inc.
    Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.

NCRI Research Using Google/Walmart Data Brings Hope for Reaching Vaccine-Reluctant Communities

Retrieved on: 
Thursday, December 9, 2021

The Network Contagion Research Institute (NCRI), a multidisciplinary research institute that uses machine learning and scaled data analysis to map contagious threats, has published new research findings that show new inroads for reaching communities that have been reluctant to take vaccines.

Key Points: 
  • The Network Contagion Research Institute (NCRI), a multidisciplinary research institute that uses machine learning and scaled data analysis to map contagious threats, has published new research findings that show new inroads for reaching communities that have been reluctant to take vaccines.
  • Reaching these populations has become more critical with the arrival of the Omicron Covid variant, which experts believe may asymmetrically impact minority communities.
  • In addition to Google search trends, social media comments, and aggregated event/demographic databases, the research combined data from the CDC on vaccination rates with Walmart's data on vaccine distribution.
  • Peter Norvig, Director of Research at Google, a professor at Stanford, and NCRI research contributor, said, "the NCRI is demonstrating how smart analysis of data can strengthen our dialogue across the country in the effort to beat COVID-19.